Overview
On September 9, 2021, the Department of Health and Human Services (HHS) announced an amendment to the COVID-19 Public Readiness and Emergency Preparedness (PREP) Act declaration to allow licensed pharmacists, pharmacy interns, and pharmacy technicians to order and administer select COVID-19 therapeutics, including subcutaneous monoclonal antibodies.
The U.S. Food and Drug Administration has issued several Emergency Use Authorizations for the use of anti-SARS-CoV-2 monoclonal antibodies – bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. Licensed pharmacists are now authorized to both order and administer monoclonal antibodies as COVID-19 therapeutics. We’ll review the clinical evaluation of indications and contraindications for COVID-19 therapeutics, adverse events, as well as and product-specific requirements or considerations related to FDA approval, authorization, clearance, or licensing of COVID-19 therapeutics.
This training program is designed to fully satisfy the requirements of the PREP Act by supplementing APhA’s Pharmacy-based Immunization Delivery certificate training program.
Speaker
Registration Rates
VPhA Member: $10
Non-Member: $30